Written by the Nuvirox Research Team
Key Points
- Urolithin A improves mitochondrial function in human cartilage cells and reduces cartilage damage in animal models of osteoarthritis — but that evidence is preclinical, not from a human joint trial.
- Two published human trials show urolithin A improves muscle strength and mitochondrial health markers in middle-aged and older adults, though neither measured joint pain or cartilage as an outcome.
- If you want to try it, treat it the way you'd treat any promising-but-unproven longevity compound: reasonable safety data, genuinely interesting mechanism, no completed human joint-pain trial to point to yet.
Short answer: the cell and animal data are genuinely impressive, but there is no published human trial showing urolithin A improves joint pain or slows osteoarthritis in people. What exists is a solid mechanistic story — urolithin A activates mitophagy (the process that clears out worn-down mitochondria) in cartilage cells — plus two human trials in unrelated outcomes (muscle strength, exercise performance) that establish it's safe and bioavailable at typical supplement doses. The joint-specific human trial hasn't been run yet.
What is urolithin A, and why would it affect joints at all?
Urolithin A isn't something you eat directly. It's a compound your gut bacteria produce when they break down ellagitannins, plant compounds found in pomegranates, walnuts, and certain berries. Whether you actually produce meaningful amounts depends heavily on your gut microbiome — a large share of people are "low producers," which is the main reason supplement companies sell it as a purified postbiotic rather than telling people to eat more pomegranate.
The joint connection comes from aging biology. As cartilage cells (chondrocytes) age, their mitochondria — the structures that produce cellular energy — accumulate damage and stop being efficiently recycled. That decline in "mitophagy" is considered one of the hallmarks of osteoarthritis at the cellular level. Urolithin A is one of the few compounds shown to directly restart mitophagy in aging cells, which is why cartilage researchers got interested.
What does the actual joint research show?
The key study here is a 2022 Aging Cell paper from a team including researchers at Scripps Research. They treated human cartilage cells — taken from both healthy donors and osteoarthritis patients — with urolithin A and found it improved mitophagy and mitochondrial respiration in the cells. They then gave urolithin A to mice with surgically induced osteoarthritis for two months and found it reduced cartilage degeneration, calmed synovial inflammation, and eased pain behavior in the animals.
That's a real, peer-reviewed, carefully done study. It is also, by the authors' own framing, a call for the human trials to be done — not a substitute for them. The paper's own discussion section states plainly that there are, as of publication, no drugs successfully tested in human osteoarthritis trials for both symptom relief and disease modification, and explicitly calls for clinical studies of urolithin A in OA patients to follow.
What do the human trials that do exist actually measure?
Two human randomized controlled trials of urolithin A (marketed as Mitopure) have been published, and it's worth being precise about what they tested. A 2022 trial in Cell Reports Medicine gave middle-aged adults urolithin A for four months and found roughly a 12% improvement in muscle strength, along with better aerobic endurance and biomarkers of mitochondrial health. A separate 2022 trial in JAMA Network Open looked at older adults and found improvements in muscle endurance and mitochondrial health markers. Neither trial enrolled people for joint pain, and neither measured cartilage, osteoarthritis symptoms, or joint function as an outcome. They're useful for establishing safety and that the compound does what it's supposed to do biologically — they're not evidence it helps joints in people.
What would need to happen for this to become a confident "yes"
A proper answer requires a randomized, placebo-controlled trial in people with knee or hand osteoarthritis, using validated pain and function scores (like WOMAC) as the primary outcome, ideally with imaging or biomarker measures of cartilage over months rather than weeks. That trial doesn't exist yet in the published literature as of this writing. Until it does, urolithin A sits in the same category as several other compounds this cluster has covered — strong lab and animal signal, safety established in unrelated human trials, joint-specific human proof still pending.
What Joint+ Restore won't do
No supplement, urolithin A included, will regrow cartilage that's already worn down, and none should be treated as a substitute for medical evaluation if you have new, severe, or one-sided joint swelling, warmth, fever, or pain that wakes you up at night — those warrant a doctor's visit to rule out infection, gout, or inflammatory arthritis rather than a supplement trial.
Dosing and what a reasonable trial run looks like
The published human trials used 500–1,000 mg of urolithin A per day for 4 months. Effects on muscle strength and mitochondrial biomarkers in those trials took roughly 4 months to become measurable, which is a reasonable window to think about for any outcome you're personally tracking, joint-related or otherwise, since there's no published joint-specific dosing or timeline data to lean on instead.
It's also worth noting how urolithin A fits into the broader picture of mitochondria-targeted longevity compounds this cluster has covered. Fisetin's first human knee trial came back flat, and spermidine's joint evidence is still preclinical as well — urolithin A is arguably ahead of both in terms of the depth of its preclinical cartilage-specific data, but it hasn't cleared the human-trial bar that would separate it from that pack. If you're someone who tracks emerging longevity research generally, that context is useful for calibrating expectations rather than treating any one compound in this category as a proven joint fix.
Frequently asked questions
Is urolithin A the same as pomegranate extract? No. Pomegranate contains the precursor compounds (ellagitannins), but whether your gut converts them into urolithin A depends on your individual microbiome. Most people are considered low producers, which is why purified urolithin A supplements exist separately from pomegranate extract.
Is it safe to take long-term? The published human trials (up to 4 months) reported it as well tolerated with no significant safety signals, though "long-term" in the sense of years hasn't been specifically studied.
Should I take it instead of glucosamine or collagen? There isn't a head-to-head human trial comparing urolithin A to more established joint ingredients, so that's not a question the evidence can currently answer. See our comparison of collagen and glucosamine for the ingredients that do have joint-specific human trial data.
Does urolithin A interact with other supplements, like fisetin or spermidine? No documented interactions, but as with our piece on NAD+ decline and joint aging, these are all still-emerging areas where combination research is limited.
From Nuvirox
Why we formulated Joint+ Restore
Nuvirox is currently reformulating Joint+ Restore, so rather than list ingredients that may change, here's the short version: our research team builds each formula around the joint-support compounds that show up most consistently in published human research, at doses that reflect that research rather than marketing round numbers.
Every order is backed by our 60-day money-back guarantee — long enough to actually evaluate it the way the research on joint supplements says you should, rather than judging it after a week.
Learn more about Joint+ Restore →The bottom line
Urolithin A has one of the more compelling mechanistic stories in the joint-supplement world right now: real chondrocyte data, a real animal osteoarthritis model, and a plausible reason it should matter as cartilage ages. What it doesn't have yet is the human osteoarthritis trial that would actually confirm the story translates to people. If you're drawn to the mitochondrial-aging angle, it's a reasonable, low-risk compound to try — just go in knowing you're ahead of the evidence, not behind it.
References
- D’Amico D, Olmer M, Fouassier AM, et al. Urolithin A improves mitochondrial health, reduces cartilage degeneration, and alleviates pain in osteoarthritis. Aging Cell. 2022;21(8):e13662. PMID: 35778837.
- Singh A, D’Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med. 2022;3(5):100633. PMID: 35584623.
- Liu S, D’Amico D, Shankland E, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA Netw Open. 2022;5(1):e2144279.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.